Login to Your Account

Terminated Deal

Happy Return? Teva Saying No to 'De-risked' Rexahn Therapy

By Randy Osborne
Staff Writer

Thursday, August 29, 2013
Rexahn Pharmaceuticals Inc. is going ahead with development of RX-3117 after Teva Pharmaceutical Industries Ltd. declined its option to continue with the cancer therapy, which proved orally bioavailable with no adverse events in a small, European Phase I trial.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription